Press "Enter" to skip to content

Novel Strategies Explored to Optimize Osimertinib Treatment and Beyond in EGFR+ NSCLC – OncLive

admin 0

Novel Strategies Explored to Optimize Osimertinib Treatment and Beyond in EGFR+ NSCLC  OncLive

Mark G. Kris, MD, discusses the latest data with osimertinib (Tagrisso) and shared unanswered questions that remain in EGFR-positive non–small cell lung …

“lung cancer” – Google News

(Visited 1 times, 1 visits today)

Leave a Reply

Your email address will not be published. Required fields are marked *